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Objective
To investigate HIV drug resistance and its influencing fac-
tors, and then provide scientific evidence for antiretroviral
therapy and reducing drug resistance.
Methods
Questionnaires and blood sample collection for drug
resistance detection were conducted among 109 treated
cases and 84 non-treated cases. Viral load was detected by
NASBA and drug resistance was measured by nested PCR.
Results
The viral load of 95 cases (27 treated cases and 68 non-
treated cases) was more than 1 000 copies/ml. The rate of
drug resistance of treated and non-treated group was
40.74% and10.29% respectively (see Table 1). The rate of
different drug resistance was higher significantly in treated
group than in no-treated group. However, the sensitive of
different drug resistance was lower significantly in treated
group than in no-treated group (see Table 2). Therapy
schedule of 17 treated cases was stopped due to a variety
of reasons, such as death, dizziness, liver damage, belly-
ache, et al (see Table 3). Except for five death cases, two
suicides were discovered at 16 and 42 days respectively
after stopping therapy.
Conclusion
Antiviral therapy can effectively reduce the viral load and
inhibit viral replication. Drug resistance exists differently
among treated and non-treated HIV/AIDS cases. HIV gene
mutation may be the key reason for drug resistance.
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Table 1: The results of drug resistance detection in 95 cases with AIDS
Group No. Low-midrange resistance 
(%)
Height drug resistance (%) Total of resistance (%)
Stopping therapy 12 0 (0.00) 3 (25.00) 3 (25.00)
Single therapy 11 0 (0.00) 6 (54.55) 6 (54.55)
Therapeutic alliance 4 0 (0.00) 2 (50.00) 2 (50.00)
No therapy 68 6 (8.82) 1 (1.47) 7 (10.29)Retrovirology 2009, 6(Suppl 2):P94 http://www.retrovirology.com/content/6/S2/P94
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Table 2: The results of resistance detection of different drugs among 95 cases
Drug resistance
Group Drug No. Sensitive (%) Low 
resistance
Midrange 
resistance
Height 
resistance
Latent 
resistance
Total (%)
T h e r a p y D D I 2 7 1 9  ( 7 0 . 3 7 ) 1160 8  ( 2 9 . 6 3 )
D 4 T 2 7 2 4  ( 8 8 . 8 9 ) 2100 3  ( 1 1 . 1 1 )
E F V 2 7 1 5  ( 5 5 . 5 6 ) 0192 1 2  ( 4 4 . 4 4 )
NVP 27 16 (59.26) 0 0 10 1 11 (40.74)
N o  t h e r a p y D D I 6 8 6 6  ( 9 7 . 0 6 ) 1003 4  ( 5 . 8 8 )
D 4 T 6 8 6 8  ( 1 0 0 . 0 0 ) 1004 5  ( 7 . 3 5 )
E F V 6 8 6 5  ( 9 5 . 5 8 ) 1200 3  ( 4 . 4 1 )
N V P 6 8 6 5  ( 9 5 . 5 8 ) 1210 3  ( 4 . 4 1 )
Table 3: The reasons of stopping therapy
Course of 
treatment 
(Months)
Death Liver damage Dizziness Skin damage Bellyache Total (%)
0∼ 113-- 5  ( 2 9 . 4 1 )
1∼ 22111 7  ( 4 1 . 1 8 )
2∼ 2-1-- 3  ( 1 7 . 6 5 )
…
7∼ 11 2  ( 1 1 . 7 6 )
Total (%) 5 (29.41) 4 (23.53) 5 (29.41) 2 (11.76) 1 (5.88) 17 (100)